Free Trial
NASDAQ:ADXN

Addex Therapeutics Q1 2025 Earnings Report

Addex Therapeutics logo
$7.99 -0.22 (-2.63%)
Closing price 05/28/2025 03:56 PM Eastern
Extended Trading
$8.08 +0.09 (+1.06%)
As of 05/28/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Addex Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Addex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Addex Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, June 2, 2025
Conference Call Time
6:00AM ET

Conference Call Resources

Addex Therapeutics Earnings Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
See More Addex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Addex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Addex Therapeutics and other key companies, straight to your email.

About Addex Therapeutics

Addex Therapeutics (NASDAQ:ADXN) discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

View Addex Therapeutics Profile

More Earnings Resources from MarketBeat